Media coverage about Alimera Sciences (NASDAQ:ALIM) has trended positive this week, AlphaOne reports. The research firm, a unit of Accern, rates the sentiment of news coverage by monitoring more than twenty million blog and news sources in real time. AlphaOne ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Alimera Sciences earned a daily sentiment score of 0.44 on AlphaOne’s scale. AlphaOne also assigned media stories about the biopharmaceutical company an impact score of 100 out of 100, meaning that recent news coverage is extremely likely to have an impact on the company’s share price in the next several days.
These are some of the news articles that may have impacted AlphaOne’s analysis:
- Alimera Sciences : Research Reports Initiation on Drug Makers Stocks — Impax Labs, Sanofi, Heron Therapeutics, and Alimera Sciences (4-traders.com)
- MF Rank in Focus for Alimera Sciences, Inc. (NASDAQ:ALIM) – Lenox Ledger (lenoxledger.com)
- Brokerages Anticipate Alimera Sciences Inc (ALIM) Will Announce Earnings of -$0.07 Per Share (americanbankingnews.com)
- First Horizon National Reports 13% Gain In Q1 Bottom Line (cote-ivoire.com)
- Alimera Sciences, Inc. (NASDAQ:ALIM) held by 19 SEC 13F Filers – Post Analyst (postanalyst.com)
Alimera Sciences (NASDAQ:ALIM) traded up 2.19% during mid-day trading on Thursday, hitting $1.40. 227,343 shares of the stock were exchanged. The stock’s market cap is $90.81 million. The company has a 50 day moving average price of $1.42 and a 200 day moving average price of $1.27. Alimera Sciences has a 52 week low of $1.01 and a 52 week high of $5.15.
Alimera Sciences (NASDAQ:ALIM) last posted its quarterly earnings results on Wednesday, March 1st. The biopharmaceutical company reported ($0.10) EPS for the quarter, missing analysts’ consensus estimates of ($0.07) by $0.03. The firm earned $10.70 million during the quarter, compared to the consensus estimate of $10.60 million. During the same period in the prior year, the business earned ($0.24) earnings per share. The business’s quarterly revenue was up 84.5% compared to the same quarter last year. Analysts expect that Alimera Sciences will post ($0.18) EPS for the current fiscal year.
Several equities research analysts recently issued reports on the stock. Zacks Investment Research raised shares of Alimera Sciences from a “sell” rating to a “hold” rating in a research report on Friday, March 24th. Cowen and Company set a $3.00 price target on shares of Alimera Sciences and gave the company a “buy” rating in a report on Thursday, March 2nd.
In other news, CEO C. Daniel Myers sold 21,172 shares of the business’s stock in a transaction on Friday, March 10th. The stock was sold at an average price of $1.39, for a total transaction of $29,429.08. Following the completion of the transaction, the chief executive officer now owns 180,861 shares of the company’s stock, valued at approximately $251,396.79. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. 14.00% of the stock is currently owned by insiders.
About Alimera Sciences
Alimera Sciences, Inc (Alimera) is a pharmaceutical company. The Company is engaged in the research, development and commercialization of prescription ophthalmic pharmaceuticals. The Company operates through two segments: U.S. and International. The Company focuses on diseases affecting the back of the eye or retina.
Receive News & Ratings for Alimera Sciences Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alimera Sciences Inc and related companies with MarketBeat.com's FREE daily email newsletter.